aTyr Pharma (471A) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Efzofitimod 450 Mg, Efzofitimod 270 Mg | Interstitial Lung Disease | Phase II | Recruiting | Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD) | May 12, 2023 | ― |
| Efzofitimod 3 Mg/Kg, Efzofitimod 5 Mg/Kg | Pulmonary Sarcoidosis | Phase III | Active Not Recruiting | Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis | Jun 08, 2022 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Efzofitimod 450 Mg, Efzofitimod 270 Mg | Phase II | Interstitial Lung Disease | Recruiting | Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD) | May 12, 2023 | ― |
| Efzofitimod 3 Mg/Kg, Efzofitimod 5 Mg/Kg | Phase III | Pulmonary Sarcoidosis | Active Not Recruiting | Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis | Jun 08, 2022 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Atyr Pharma Inc. (DE:471A) have in its pipeline
aTyr Pharma DE:471A is currently developing the following drugs: Efzofitimod 450 Mg, Efzofitimod 270 Mg, Efzofitimod 3 Mg/Kg, Efzofitimod 5 Mg/Kg. These drug candidates are in various stages of clinical development as the company works toward FDA approval.